You are here: Home » Products » API » Cardiovascular APIS » Levosimendan » Levosimendan



CAS No.:141505-33-1
Type:Pharmaceutical API
Certificate:GMP, COPP, WC, DMF
Shelf Life:2 years
Quality Standard:CP, EP, JP, USP
Chemical Name:2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl] phenyl] hydrazinylidene]propanedinitrile
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Levosimendan is a hydrazone, a pyridazinone and a nitrile. It has a role as a vasodilator agent, an EC (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor, a cardiotonic drug and an anti-arrhythmia drug.


Levosimendan is a medication used primarily for the management of acute decompensated heart failure (ADHF) and certain cases of cardiogenic shock. Its main function is to enhance the contractility of the heart muscle and dilate blood vessels, leading to improved cardiac output and increased blood flow to vital organs. Here are the main functions of Levosimendan:

Calcium Sensitization: Levosimendan works as a calcium sensitizer, which means it increases the sensitivity of the cardiac muscle cells to calcium. Calcium plays a crucial role in the contraction of heart muscle fibers. By making the cardiac muscle more responsive to calcium, Levosimendan enhances the force of contraction, improving the heart's pumping ability. This is particularly beneficial in cases of acute heart failure where the heart's pumping function is compromised.

Vasodilation: Levosimendan causes relaxation and dilation of blood vessels, particularly in the arteries and veins. This vasodilatory effect reduces the resistance in the blood vessels, lowering the workload on the heart. As a result, the heart doesn't have to pump as hard against resistance, leading to increased blood flow throughout the body, including to vital organs like the kidneys and brain.

Positive Inotropic Effect: Levosimendan has a positive inotropic effect, meaning it increases the force of cardiac contraction without significantly increasing oxygen demand. This is an advantage over traditional inotropic agents, which can increase oxygen demand and potentially worsen ischemia (reduced blood flow) in the heart muscle.

Cardioprotective Effects: In addition to its inotropic and vasodilatory effects, Levosimendan has been associated with certain cardioprotective properties, such as reducing oxidative stress and improving cellular energy production in heart muscle cells.


0.5kg/bag or 1kg/bag or according to customer’s requirements.

Related Products

Related News

content is empty!

Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.



Copyright © 2023 Shandong Loncom Pharmaceutical Co., Ltd. All Rights Reserved. Sitemap | Privacy Policy
Supported by leadong.com
Contact Us